Commission Delegated Regulation (EU) 2021/1760 of 26 May 2021 supplementing Regulation (EU) 2019/6 of the European Parliament and of the Council by establishing the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans
Proposed act with possible EEA relevance
Act under scrutiny by EEA EFTA
Draft Joint Committee Decision (JCD) under consideration
Entry into force of Joint Committee Decision (JCD) pending
Incorporated into the EEA Agreement and in force
Incorporated into the EEA Agreement but no longer in force
Legal status
Draft Joint Committee Decision (JCD) under consideration by the EU (EEAS) and the EFTA States (Iceland, Liechtenstein and Norway) Area (EEA Agreement)
II Technical Regulations, Standards, Testing and Certification
II.XIII Medicinal Products
Legal documents
Commission Delegated Regulation (EU) 2021/1760 of 26 May 2021 supplementing Regulation (EU) 2019/6 of the European Parliament and of the Council by establishing the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans
Delegierte Verordnung (EU) 2021/1760 der Kommission vom 26. Mai 2021 zur Ergänzung der Verordnung (EU) 2019/6 des Europäischen Parlaments und des Rates durch die Festlegung der Kriterien für die Bestimmung antimikrobieller Wirkstoffe, die der Behandlung bestimmter Infektionen beim Menschen vorbehalten bleiben müssen
History
27.04.2022
Draft Joint Commitee Decision (JCD) incorporating the act into the EEA Agreement sent to Commission
26.05.2021
Adoption date in the EU
28.01.2022
Compliance date in the EU
Disclaimer: EEA-Lex is provided for information purposes only. The information is not guaranteed or promised to be current or complete and is not intended to replace any applicable legal sources.